KASID
Search
- Page Path
- HOME > Search
Review
- Miscellaneous
- Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies
- Priscila A. Lima, Bárbara B. Berg, Marina Gomes Miranda e Castor
- Intest Res 2022;20(4):392-417. Published online May 31, 2022
- DOI: https://doi.org/10.5217/ir.2021.00160
-
Abstract
PDF
PubReader
ePub - The components of the endogenous cannabinoid system are widely expressed in the gastrointestinal tract contributing to local homeostasis. In general, cannabinoids exert inhibitory actions in the gastrointestinal tract, inducing anti-inflammatory, antiemetic, antisecretory, and antiproliferative effects. Therefore, cannabinoids are interesting pharmacological compounds for the treatment of several acute intestinal disorders, such as dysmotility, emesis, and abdominal pain. Likewise, the role of cannabinoids in the treatment of chronic intestinal diseases, such as irritable bowel syndrome and inflammatory bowel disease, is also under investigation. Patients with chronic intestinal inflammatory diseases present impaired quality of life, and mental health issues are commonly associated with long-term chronic diseases. The complex pathophysiology of these diseases contributes to difficulties in diagnosis and, therefore, in the choice of a satisfactory treatment. Thus, this article reviews the involvement of the cannabinoid system in chronic inflammatory diseases that affect the gastrointestinal tract and highlights possible therapeutic approaches related to the use of cannabinoids.
-
Citations
Citations to this article as recorded by
- The endocannabinoid system likely regulates enteric neuronal death by inhibiting the activation of the s100β/RAGE/NF-κB complex during inflammatory bowel disease
Antônio Kleiton de Sousa, Ana Clara Coelho da Costa, Adão Santiago de Sousa Oliveira, Thereza Fernanda Conceição de Sousa, Rafael da Silva Prudênio, Lara da Cunha Muniz, Gabriel da Cruz Santos, Danyela Maria Leal Rocha, Stefany Guimarães Sousa, Diva de Ag
Medical Hypotheses.2026; 206: 111849. CrossRef -
Cannabis sativa
alleviates experimentally acetic acid- induced ulcerative colitis in rats: targeting CB1/SIRT/MAPK signaling pathways
Rania Elgohary, Enayat A. Omara, Abeer Salama
Immunopharmacology and Immunotoxicology.2025; 47(1): 120. CrossRef - USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A REVIEW OF CLINICAL AND INTERVENTION STUDIES
Anita Janda, Magdalena Rosiewicz, Marcin Durowicz, Iwona Górnicka, Aleksandra Pastuszek, Karolina Bieńkowska, Jan Drzymała, Urszula Kierepka, Sylwia Bartolik
International Journal of Innovative Technologies in Social Science.2025;[Epub] CrossRef - Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet
Klaudia Sztolsztener, Ewa Harasim-Symbor, Adrian Chabowski, Karolina Konstantynowicz-Nowicka
Biomedicine & Pharmacotherapy.2024; 178: 117286. CrossRef - Metabolomics analysis of extracellular vesicles derived from bovine colostrum and mature milk
Sitong Zhang, Xipeng Sun, Yameng Zhang, Rong Huang, Wenyou Situ, Huaxi Yi, Lingjun Tong
Food Science of Animal Products.2024; 2(3): 9240078. CrossRef - Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases
Dinesh Thapa, Leon N. Warne, Marco Falasca
International Journal of Molecular Sciences.2023; 24(19): 14677. CrossRef
- The endocannabinoid system likely regulates enteric neuronal death by inhibiting the activation of the s100β/RAGE/NF-κB complex during inflammatory bowel disease
- 13,142 View
- 402 Download
- 7 Web of Science
- 6 Crossref
First
Prev
